Agenus shared a post on LinkedIn:
“We are excited to announce our Virtual Stakeholder Briefing on Wednesday, August 27, 2025, at 4:00 PM ET.
Join us to hear from our leadership team, including Founder & CEO Garo H. Armen, PhD, and leading oncology experts from Duke University and the Canadian Cancer Trials Group. The agenda will cover:
- Strategic and Q2 2025 financial overview
- Achievements towards Zydus partnership closing, advancing botensilimab (BOT) and balstilimab (BAL)
- Launch of the pivotal Phase 3 BATTMAN study in metastatic colorectal cancer (CRC)
- Patient-driven innovations and upcoming immuno-oncology milestones
Register for the webcast.
Webcast link.”
More posts featuring Agenus.